Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HLA-DRA Antikörper

HLA-DRA Reaktivität: Human, Affe FACS, IF Wirt: Maus Monoclonal IPO-10 unconjugated
Produktnummer ABIN6939635
  • Target Alle HLA-DRA Antikörper anzeigen
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Reaktivität
    • 88
    • 16
    • 10
    • 10
    • 9
    • 9
    • 3
    • 2
    • 2
    • 1
    Human, Affe
    Wirt
    • 56
    • 47
    • 1
    • 1
    Maus
    Klonalität
    • 57
    • 48
    Monoklonal
    Konjugat
    • 53
    • 12
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    Dieser HLA-DRA Antikörper ist unkonjugiert
    Applikation
    • 48
    • 48
    • 34
    • 32
    • 18
    • 12
    • 11
    • 10
    • 9
    • 5
    • 3
    • 3
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF)
    Spezifität
    MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50 % of cells). The MAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This MAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70 % of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected. '
    Aufreinigung
    Purified by Protein A/G
    Immunogen
    Spleen cells of a patient with hairy cell leukemia (Daudi cells)
    Klon
    IPO-10
    Isotyp
    IgG3 kappa
    Top Product
    Discover our top product HLA-DRA Primärantikörper
  • Applikationshinweise

    Positive Control: Ramos, Daudi or HuT78 cells. Tonsil or lymph node.

    Known Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Optimal dilution for a specific application should be determined.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    200 μg/mL
    Buffer
    10 mM PBS with 0.05 % BSA & 0.05 % azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-80 °C
    Informationen zur Lagerung
    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
    Haltbarkeit
    24 months
  • Target
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Andere Bezeichnung
    HLA-DRA (HLA-DRA Produkte)
    Molekulargewicht
    ~36kDa
    Gen-ID
    3122
    UniProt
    P01903
    Pathways
    T-Zell Rezeptor Signalweg, CXCR4-mediated Signaling Events
Sie sind hier:
Kundenservice